In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

The results of gene therapy for hemophilia B contrast with those of factor replacement therapies, where lifelong infusions ...

A study by UK-based scientists has confirmed that a gene transfer approach to treating haemophilia B remains safe and ...

Gene therapy has proved to be a safe long-term treatment for haemophilia B. The benefits of a single dose persist for at ...

While commercial uptake by patients still lags and a recent court decision rekindles a legal battle, clinical successes ...

Successful immune tolerance induction (ITI) in hemophilia A patients with inhibitors led to lower treatment costs, a study ...

Columnist Jennifer Lynne argues that her health is not defined by her diagnoses, and in fact those terms can often be too limited.

In a major breakthrough, UK-based researchers have found that a one-time gene therapy approach for haemophilia B remains safe ...

Learn how clotting factor therapy, gene therapy, and non-factor treatments are improving hemophilia prognosis and life expectancy.

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...